Tc
Fri, Jan-19-07, 17:18
http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20070118/-
hypertension_070118/20070118?hub=Health
Blood pressure guidelines create new danger zone Updated Thu.
Jan. 18 2007 11:25 PM ET
CTV.ca News Staff
New research suggests that people with so-called "high-normal"
blood pressure should seek treatment, prompting revised
guidelines for preventing hypertension.
"We now have evidence that people in the high-normal upper
range of blood pressure are more likely to develop
hypertension," Dr. Sheldon Tobe, of the Heart and Stroke
Foundation, told CTV News.
He added that "40 per cent will develop hypertension within
two years."
High blood pressure, or hypertension, is one of the leading
causes of death in Canada. It puts patients at greater risk
for heart attacks, strokes, kidney failure and even dementia.
It's estimated that about 5 million Canadians have the
condition, meaning their blood pressure exceeds 140/90 -- a
measurement that looks at systolic and diastolic pressure.
A normal blood pressure reading is 120/80 or less.
Canadians who have high-normal blood pressure have a
systolic reading between 130 and 139, and a diastolic
reading between 85 and 89.
According to the Heart and Stroke Foundation, about 2.5
million Canadians have high-normal blood pressure.
"And the new information we have is that . . . about half of
people with high-normal blood pressure will develop full-blown
hypertension in four years," Tobe told The Canadian Press.
He added that hypertension is also a condition that affects
young men -- about one in 10 of those aged 18 to 35 have high
blood pressure, according to a Canadian Heart Health Survey.
"Many of these young men go undiagnosed because they're
(otherwise) healthy and they often don't see their family
doctors," said Tobe.
"And if they do, it's not to have their blood pressure
checked."
But after the age of 65, more women have hypertension than
men. Researchers believe that's because elderly women have
lost the effects of estrogen and other sex hormones.
"So if we can screen for hypertension in women as they're
getting older, postmenopausal, that's where we can identify
women who have high-normal blood pressure and help to get them
enamoured with lifestyle interventions, and perhaps we could
help prevent them from developing hypertension altogether,"
Tobe told CP.
"If they start early, perhaps they will not need medication at
all or could delay the need for it by years or decades."
The Heart and Stroke Foundation now has the following
guidelines:
People with high-normal blood pressure should have it checked
at least once a year; All Canadians should have their blood
pressure checked during visits to the doctor; About 40 per
cent of overweight Canadians with high-normal blood pressure
will develop full-blown hypertension within two years, and 60
per cent within four years; Canadians should reduce their salt
intake to less than 2,300 milligrams a day -- too much sodium
can cause hypertension; and, An active, healthy lifestyle --
including regular physical activity -- is urged to prevent
high blood pressure.
*************
About Dr. Tobe:
http://japan.medscape.com/viewarticle/481801
Disclosure: Sheldon W. Tobe, MD, FRCPC, has disclosed that he
has received grants for clinical research and grants for
educational activities from Gotham/Pfizer Canada. Dr. Tobe has
reported that he does not discuss any investigational or
unlabeled uses of commercial products in this activity.
**
http://www.pubmedcentral.nih.gov/articlerender.fcgi?art-
id=1435956
Support for this study was provided by the Canadian Institutes
of Health Research (CIHR), in partnership with Pfizer Canada.
**
http://www.cmaj.ca/cgi/content/full/167/6/661
This project was sponsored by the Canadian Coalition for High
Blood Pressure Prevention and Control, the Canadian
Hypertension Society, the College of Family Physicians of
Canada, the Heart and Stroke Foundation of Canada, and the
Adult Disease Division and Bureau of Cardio-Respiratory
Diseases and Diabetes, Centre for Chronic Disease Prevention
and Control, Health Canada.
The work was financially supported, through unrestricted
grants, by Bayer Health Care Inc., Boehringer
Ingelheim-GlaxoSmithKline, Bristol-Myers Squibb Canada Inc.,
Crystaal, Merck Frosst Canada Inc., Novartis Pharmaceuticals
Canada Inc., Pfizer Canada Inc., Servier Canada Inc. and
Solvay Pharma.
Competing interests: Drs. Campbell, Feldman and Drouin are
paid consultants for several companies that manufacture drugs
used in the treatment of hypertension and in this capacity
have received travel assistance to attend advisory board
meetings. They have also received honoraria and other
compensation from several companies for conducting research
related to the material in this article, as well as speaker
fees and educational grants.
**
http://www.newswire.ca/en/releases/archive/February2006/14/-
c2110.html
KIRKLAND, QC, Feb. 14 /CNW Telbec/ - Pfizer Canada Inc.
announced today that CADUET(TM) (amlodipine besylate and
atorvastatin calcium), the first treatment to address multiple
risk factors for cardiovascular disease, is now available in
Canada. ...............
"CADUET represents an important therapeutic advance. It will
allow physicians to help their patients with simpler dosing of
medications. Patients can have a comprehensive approach while
providing the safety and efficacy of two leading treatments in
one single pill," said Dr. Sheldon Tobe, Associate Professor
of Medicine, Nephrology, at the University of Toronto. "With
CADUET, I can help prevent the devastating cardiovascular
events from occurring in hypertensive patients with multiple
risk factors."
*****
CANADIAN HYPERTENSION EDUCATION PROGRAM
http://www.hypertension.ca/chep/whatCHEPva.html
CHEP financial support CHEP has direct and indirect funding
from the Public Health Agency of Canada and indirect funding
from the Canadian Hypertension Society and Blood Pressure
Canada. Canadian research and development pharmaceutical
companies provide equal financial support for CHEP
infrastructure each year. In 2006 the sponsors were Abbott,
Sanofi Aventis, Astra Zeneca, Bayer, Biovail, Boehringer
Ingelheim, Bristol-Myers Squibb, Merck Frosst, Novartis,
Pfizer, Servier and Solvay. CHEP also receives funding for
specific implementation projects and outcomes research
projects. In 2006 funding was received from Pfizer Canada for
production of a summary pocket booklet and from Servier Canada
for the development of a patient self care booklet. Pfizer
Canada, Merck Frosst Canada, Sanofi Aventis, Bristol Myers
Squibb and Servier Canada have funded epidemiological research
projects. CHEP associated surveillance projects have received
funding from the Public Health Agency of Canada (PHAC), the
Heart and Stroke Foundation and the Canadian Institutes for
Health Research.
***
Sounds more like the Canadian Hypertension Drug and
Sales Program.
Absolutely shameful. So much for professional and scientific
integrity.
TC
hypertension_070118/20070118?hub=Health
Blood pressure guidelines create new danger zone Updated Thu.
Jan. 18 2007 11:25 PM ET
CTV.ca News Staff
New research suggests that people with so-called "high-normal"
blood pressure should seek treatment, prompting revised
guidelines for preventing hypertension.
"We now have evidence that people in the high-normal upper
range of blood pressure are more likely to develop
hypertension," Dr. Sheldon Tobe, of the Heart and Stroke
Foundation, told CTV News.
He added that "40 per cent will develop hypertension within
two years."
High blood pressure, or hypertension, is one of the leading
causes of death in Canada. It puts patients at greater risk
for heart attacks, strokes, kidney failure and even dementia.
It's estimated that about 5 million Canadians have the
condition, meaning their blood pressure exceeds 140/90 -- a
measurement that looks at systolic and diastolic pressure.
A normal blood pressure reading is 120/80 or less.
Canadians who have high-normal blood pressure have a
systolic reading between 130 and 139, and a diastolic
reading between 85 and 89.
According to the Heart and Stroke Foundation, about 2.5
million Canadians have high-normal blood pressure.
"And the new information we have is that . . . about half of
people with high-normal blood pressure will develop full-blown
hypertension in four years," Tobe told The Canadian Press.
He added that hypertension is also a condition that affects
young men -- about one in 10 of those aged 18 to 35 have high
blood pressure, according to a Canadian Heart Health Survey.
"Many of these young men go undiagnosed because they're
(otherwise) healthy and they often don't see their family
doctors," said Tobe.
"And if they do, it's not to have their blood pressure
checked."
But after the age of 65, more women have hypertension than
men. Researchers believe that's because elderly women have
lost the effects of estrogen and other sex hormones.
"So if we can screen for hypertension in women as they're
getting older, postmenopausal, that's where we can identify
women who have high-normal blood pressure and help to get them
enamoured with lifestyle interventions, and perhaps we could
help prevent them from developing hypertension altogether,"
Tobe told CP.
"If they start early, perhaps they will not need medication at
all or could delay the need for it by years or decades."
The Heart and Stroke Foundation now has the following
guidelines:
People with high-normal blood pressure should have it checked
at least once a year; All Canadians should have their blood
pressure checked during visits to the doctor; About 40 per
cent of overweight Canadians with high-normal blood pressure
will develop full-blown hypertension within two years, and 60
per cent within four years; Canadians should reduce their salt
intake to less than 2,300 milligrams a day -- too much sodium
can cause hypertension; and, An active, healthy lifestyle --
including regular physical activity -- is urged to prevent
high blood pressure.
*************
About Dr. Tobe:
http://japan.medscape.com/viewarticle/481801
Disclosure: Sheldon W. Tobe, MD, FRCPC, has disclosed that he
has received grants for clinical research and grants for
educational activities from Gotham/Pfizer Canada. Dr. Tobe has
reported that he does not discuss any investigational or
unlabeled uses of commercial products in this activity.
**
http://www.pubmedcentral.nih.gov/articlerender.fcgi?art-
id=1435956
Support for this study was provided by the Canadian Institutes
of Health Research (CIHR), in partnership with Pfizer Canada.
**
http://www.cmaj.ca/cgi/content/full/167/6/661
This project was sponsored by the Canadian Coalition for High
Blood Pressure Prevention and Control, the Canadian
Hypertension Society, the College of Family Physicians of
Canada, the Heart and Stroke Foundation of Canada, and the
Adult Disease Division and Bureau of Cardio-Respiratory
Diseases and Diabetes, Centre for Chronic Disease Prevention
and Control, Health Canada.
The work was financially supported, through unrestricted
grants, by Bayer Health Care Inc., Boehringer
Ingelheim-GlaxoSmithKline, Bristol-Myers Squibb Canada Inc.,
Crystaal, Merck Frosst Canada Inc., Novartis Pharmaceuticals
Canada Inc., Pfizer Canada Inc., Servier Canada Inc. and
Solvay Pharma.
Competing interests: Drs. Campbell, Feldman and Drouin are
paid consultants for several companies that manufacture drugs
used in the treatment of hypertension and in this capacity
have received travel assistance to attend advisory board
meetings. They have also received honoraria and other
compensation from several companies for conducting research
related to the material in this article, as well as speaker
fees and educational grants.
**
http://www.newswire.ca/en/releases/archive/February2006/14/-
c2110.html
KIRKLAND, QC, Feb. 14 /CNW Telbec/ - Pfizer Canada Inc.
announced today that CADUET(TM) (amlodipine besylate and
atorvastatin calcium), the first treatment to address multiple
risk factors for cardiovascular disease, is now available in
Canada. ...............
"CADUET represents an important therapeutic advance. It will
allow physicians to help their patients with simpler dosing of
medications. Patients can have a comprehensive approach while
providing the safety and efficacy of two leading treatments in
one single pill," said Dr. Sheldon Tobe, Associate Professor
of Medicine, Nephrology, at the University of Toronto. "With
CADUET, I can help prevent the devastating cardiovascular
events from occurring in hypertensive patients with multiple
risk factors."
*****
CANADIAN HYPERTENSION EDUCATION PROGRAM
http://www.hypertension.ca/chep/whatCHEPva.html
CHEP financial support CHEP has direct and indirect funding
from the Public Health Agency of Canada and indirect funding
from the Canadian Hypertension Society and Blood Pressure
Canada. Canadian research and development pharmaceutical
companies provide equal financial support for CHEP
infrastructure each year. In 2006 the sponsors were Abbott,
Sanofi Aventis, Astra Zeneca, Bayer, Biovail, Boehringer
Ingelheim, Bristol-Myers Squibb, Merck Frosst, Novartis,
Pfizer, Servier and Solvay. CHEP also receives funding for
specific implementation projects and outcomes research
projects. In 2006 funding was received from Pfizer Canada for
production of a summary pocket booklet and from Servier Canada
for the development of a patient self care booklet. Pfizer
Canada, Merck Frosst Canada, Sanofi Aventis, Bristol Myers
Squibb and Servier Canada have funded epidemiological research
projects. CHEP associated surveillance projects have received
funding from the Public Health Agency of Canada (PHAC), the
Heart and Stroke Foundation and the Canadian Institutes for
Health Research.
***
Sounds more like the Canadian Hypertension Drug and
Sales Program.
Absolutely shameful. So much for professional and scientific
integrity.
TC